Trials / Completed
CompletedNCT00141180
CP-481,715 Nickel Allergy Study.
Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-481,715 |
Timeline
- Start date
- 2003-09-01
- Completion
- 2005-10-01
- First posted
- 2005-09-01
- Last updated
- 2006-07-25
Locations
5 sites across 2 countries: United States, Denmark
Source: ClinicalTrials.gov record NCT00141180. Inclusion in this directory is not an endorsement.